Seroatlas · Human Serome Atlas

FHL2

Four and a half LIM domains protein 2

Also known as: DRAL, FHL2_HUMAN, SLIM3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14192
Gene: FHL2
Ensembl: ENSG00000115641
Chromosome: 2
Canonical length: 279 aa
Protein class: Predicted intracellular proteins
Subcellular location: Actin filaments,Focal adhesion sites

OverviewNCBI Gene

This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. This protein is thought to have a role in the assembly of extracellular membranes. Also, this gene is down-regulated during transformation of normal myoblasts to rhabdomyosarcoma cells and the encoded protein may function as a link between presenilin-2 and an intracellular signaling pathway. Multiple alternatively spliced variants encoding different isoforms have been identified. [provided by RefSeq, Jan 2016]

Canonical amino-acid sequenceUniProt

279 residues, UniProt reviewed canonical sequence.

>Q14192|FHL2
     1  MTERFDCHHC NESLFGKKYI LREESPYCVV CFETLFANTC EECGKPIGCD CKDLSYKDRH
    61  WHEACFHCSQ CRNSLVDKPF AAKEDQLLCT DCYSNEYSSK CQECKKTIMP GTRKMEYKGS
   121  SWHETCFICH RCQQPIGTKS FIPKDNQNFC VPCYEKQHAM QCVQCKKPIT TGGVTYREQP
   181  WHKECFVCTA CRKQLSGQRF TARDDFAYCL NCFCDLYAKK CAGCTNPISG LGGTKYISFE
   241  ERQWHNDCFN CKKCSLSLVG RGFLTERDDI LCPDCGKDI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FHL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 1,338 nTPM

Expression across tissuesHPA

Tissue

heart muscle: 1,338 nTPM
ovary: 514 nTPM
tongue: 111 nTPM
cervix: 102 nTPM
urinary bladder: 99 nTPM
stomach: 90 nTPM

Single-cell type

cardiomyocytes: 3,363 nCPM
peritubular myoid cells: 1,237 nCPM
ovarian stromal cells: 1,039 nCPM
extravillous trophoblasts: 1,005 nCPM
leydig cells: 746 nCPM
epididymal efferent duct ciliated cells: 633 nCPM

Immune cell

basophil: 5.1 nTPM
T-reg: 2.6 nTPM
memory CD8 T-cell: 2 nTPM
neutrophil: 1.9 nTPM
total PBMC: 1.5 nTPM
naive CD8 T-cell: 1.4 nTPM

Brain region

hippocampal formation: 30 nTPM
cerebral cortex: 28 nTPM
choroid plexus: 23 nTPM
white matter: 17 nTPM
basal ganglia: 13 nTPM
amygdala: 9.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.13
gnomAD pLI: 0
gnomAD missense Z: 0.9
DepMap mean gene effect: -0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FHL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FHL2 as an antibody target. Whether an autoantibody or antibody against FHL2 could matter depends on whether native FHL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FHL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FHL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...